Joachim Hasenmaier elected to BI's board of managing directors
This article was originally published in Scrip
Boehringer Ingelheim has appointed Dr Joachim Hasenmaier to its board of managing directors. As of 1 October, Dr Hasenmaier will take responsibility for the new consumer health care and animal health board division. Prior to his appointment Dr Hasenmaier was regional business manager for Northern Europe and Canada
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.